Additional information
| Active substance | Bortezomib |
|---|---|
| Water Retention | Minimal |
| Hepatotoxicity | Low |
| Lab Test | Blood counts, liver enzymes, and renal function tests should be monitored |
| Also known as | PS-341 |
| WAREHOUSE | International Warehouse 2 |
| Blood pressure | Can cause hypotension or hypertension |
| Trade name | Velcade |
| Storage conditions | Store at 2В°C to 8В°C (36В°F to 46В°F) in original package to protect from light |
| Chemical name | [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid |
| Formula | C19H25BN4O4 |
| Substance class | Proteasome inhibitor |
| Main action | Inhibits the 26S proteasome |
| Half-life | 9 to 15 hours |
| Dosage (medical) | Typically 1.3 mg/m^2 body surface area, administered as an intravenous injection twice a week for two weeks, followed by a 10-day rest period |
| Dosage (sports) | Not applicable |
| Effects | Induces apoptosis and inhibits cell growth and proliferation |
| Side effects | Peripheral neuropathy, fatigue, gastrointestinal disturbances, thrombocytopenia, neutropenia, anemia, pyrexia |
| Use in sports | None |
| Manufacturer | Janssen-Cilag |
Prograf 5mg Astellas Pharma
Champix Starter Pack Pfizer
Fostimon (Merional) 75 (HMG) IBSA
Balkan Pharma Halotestin 10mg 100 Tabletten
Norvacs 10 mg Pfizer
FUCIDIN 500 mg Abdi Ibragim
Seretide Disckus (Advair) 500 mcg Glaxosmithkline 

Reviews
There are no reviews yet.